America First Legal Secures Settlement in Employment Discrimination Case Against Ally Financial

VICTORY — Ally Bank Removes DEI Initiatives from Public Filings; Another Major Corporation Retreats from Illegal DEI

The 45 Companies on the MAGA Anti-DEI Hit List

IBM fired white worker to fulfill diversity goals, lawsuit claims

MassBio’s Open Letter: A Massive Constraint on Biopharmaceutical Businesses

Approximately 219 companies have signed a vague and contradictory open letter urging biopharmaceutical firms to abandon their core mission. MassBio, the Massachusetts-based DEI resource center, created an open letter calling on companies and their leadership to abide by unnecessary DEI measures. These measures implement diverse BIPOC policy practices into biopharmaceutical businesses. By joining, these signatory companies don’t receive any advancements within the medical sphere but subject themselves to vague social commitments that constrain biopharma principles and objectives. The open letter holds back biopharmaceutical businesses through explicit actions: DEI requirements in recruitment, hiring, executive compensation, external partnerships, and company programming. At 1792 Exchange, we recognize these practices are bad for business because they take away from the merit expectation found within leadership. No longer is simple experience being looked at for genuine business benefit; instead, diversity becomes standard. Meaning, a new business partnership looks for diversity over merit. Furthermore, the open letter also constrains these businesses through vague commitments: using corporate influence to promote internal DEI initiatives, encouraging employees to “self-educate on racism and contribute to the race dialogue,” and establishing leadership accountability for reporting microaggressions. Biopharmaceutical companies exist to advance medicine and improve patient outcomes—not to shape social or racial …

Microsoft Directs Benevity to Drop SPLC Filter

Microsoft has directed Benevity to stop using the SPLC’s “hate map” to filter nonprofits from its employee gift-matching program. The Daily Signal credits 1792 Exchange, alongside Bowyer Research and The Heritage Foundation, for the shareholder activism that is moving companies away from discriminating against conservatives. Thanks to shareholder activism from 1792 Exchange, Bowyer Research, The Heritage Foundation, and others, a growing list of companies has directed Benevity to stop using the SPLC. The list includes American Express, AT&T, Mastercard, McDonald’s, Nvidia, and Salesforce. The full article can be found in Daily Caller.

Bowyer Research Cites 1792 Exchange Data in SPLC Shareholder Engagement Campaign

Bowyer Research used 1792 Exchange’s research to identify and engage 150+ companies connected to the SPLC, who donated directly through associated corporate foundations or probable indirect support through Benevity. Companies that donate to the SPLC, or have in recent years, need to give an account for how they plan on avoiding support to politicized organizations in the future. Companies that outsource their charitable policies to third-party providers like Benevity need to make clear whether they’re relying on SPLC diagnostics that Benevity offers as a screen. Our friends and co-laborers at 1792 Exchange identified a list of more than 150 companies connected to the SPLC, either via Benevity usage or direct donations to the SPLC. In the wake of the DOJ’s indictment of the SPLC, we sent a version of the following to those companies. The full article and letter can be found HERE.